Relationship between the ABO Blood Group and the COVID-19 Susceptibility

Jiao Zhao¹, Yan Yang², Han-Ping Huang³, Dong Li⁴, Dong-Feng Gu¹, Xiang-Feng Lu⁵, Zheng Zhang², Lei Liu², Ting Liu³, Yu-Kun Liu⁶, Yun-Jiao He¹, Bin Sun¹, Mei-Lan Wei¹, Yi-Rong Li⁷, Guang-Yu Yang⁸*, Xing-Huan Wang⁹*, Li Zhang³*, Xiao-Yang Zhou⁴*, Mingzhao Xing¹*, Peng George Wang¹*

¹School of Medicine, The Southern University of Science and Technology, Shenzhen, People’s Republic of China

²National Clinical Research Center for Infectious Diseases, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen Third People’s Hospital, Shenzhen, People’s Republic of China

³Infection Disease Department, Wuhan Jinyintan Hospital, Wuhan, China

⁴Renmin Hospital of Wuhan University, Wuhan 430060, People’s Republic of China

⁵Department of Epidemiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China

⁶School of Statistics, East China Normal University, Shanghai, People’s Republic of China

⁷Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China

⁸School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China

*These authors are considered as equally contributing first authors.

*Corresponding authors: Yang (yanggy@sjtu.edu.cn); Wang (wangxinghuan@whu.edu.cn); Zhang (zhangli080806@163.com); Zhou (xiaoyangzh@whu.edu.cn); Xing (xingmz@sustech.edu.cn); Wang (wangp6@sustech.edu.cn)

**Running Title:** ABO blood group and COVID-19

**Key Words:** ABO blood group, coronavirus, SARS-CoV-2, COVID-19, disease susceptibility
Abstract:

OBJECTIVE

To investigate the relationship between the ABO blood group and the COVID-19 susceptibility.

DESIGN

The study was conducted by comparing the blood group distribution in 2,173 patients with COVID-19 confirmed by SARS-CoV-2 test from three hospitals in Wuhan and Shenzhen, China with that in normal people from the corresponding regions. Data were analyzed using one-way ANOVA and 2-tailed $\chi^2$ and a meta-analysis was performed by random effects models.

SETTING

Three tertiary hospitals in Wuhan and Shenzhen, China.

PARTICIPANTS

A total of 1,775 patients with COVID-19, including 206 dead cases, from Wuhan Jinyintan Hospital, Wuhan, China were recruited. Another 113 and 285 patients with COVID-19 were respectively recruited from Renmin Hospital of Wuhan University, Wuhan and Shenzhen Third People’s Hospital, Shenzhen, China.

MAIN OUTCOME MEASURES

Detection of ABO blood groups, infection occurrence of SARS-CoV-2, and patient death.

RESULTS
The ABO group in 3694 normal people in Wuhan showed a distribution of 32.16%, 24.90%, 9.10% and 33.84% for A, B, AB and O, respectively, versus the distribution of 37.75%, 26.42%, 10.03% and 25.80% for A, B, AB and O, respectively, in 1,775 COVID-19 patients from Wuhan Jinyintan Hospital. The proportion of blood group A and O in COVID-19 patients were significantly higher and lower, respectively, than that in normal people (both $P < 0.001$). Similar ABO distribution pattern was observed in 398 patients from another two hospitals in Wuhan and Shenzhen. Meta-analyses on the pooled data showed that blood group A had a significantly higher risk for COVID-19 (odds ratio-OR, 1.20; 95% confidence interval-CI 1.02~1.43, $P = 0.02$) compared with non-A blood groups, whereas blood group O had a significantly lower risk for the infectious disease (OR, 0.67; 95% CI 0.60~0.75, $P < 0.001$) compared with non-O blood groups. In addition, the influence of age and gender on the ABO blood group distribution in patients with COVID-19 from two Wuhan hospitals (1,888 patients) were analyzed and found that age and gender do not have much effect on the distribution.

**CONCLUSION**

People with blood group A have a significantly higher risk for acquiring COVID-19 compared with non-A blood groups, whereas blood group O has a significantly lower risk for the infection compared with non-O blood groups.
INTRODUCTION

The novel coronavirus SARS-CoV-2, causing the new infectious disease COVID-19, is currently spreading rapidly around the world. Current clinical observation suggest that people’s age and gender are two risk factors in the susceptibility to COVID-19\(^1\). Older people and men are more susceptible to infection and development of more severe disease. However, no biological markers have been identified to predict the susceptibility to COVID-19 so far. Landsteiner’s ABO blood types are carbohydrate epitopes that are present on the surface of human cells. The antigenic determinants of A and B blood groups are trisaccharide moieties \(\text{GalNAc}\alpha_1-3-(\text{Fuc}\alpha_1,2)-\text{Gal}\beta-\) and \(\text{Gal}\alpha_1-3-(\text{Fuc}\alpha_1,2)-\text{Gal}\beta-\), while O blood group antigen is \(\text{Fuc}\alpha_1,2-\text{Gal}\beta-\). While blood types are genetically inherited, the environment factors can potentially influence which blood types in a population will be passed on more frequently to the next generation. Susceptibility of viral infection has been found to be related to ABO blood group. For example, Norwalk virus and Hepatitis B have clear blood group susceptibility\(^2,3\). It was also reported that blood group O individuals were less likely to become infected by SARS coronavirus\(^4\). Here, we investigated the relationship between the ABO blood type and the susceptibility to COVID-19 in patients from three hospitals in Wuhan and Shenzhen, China to test if the former may function as a biomarker for the latter.

METHODS

We collected and ABO-typed blood samples from 1775 patients infected with
SARS-CoV-2, including 206 dead cases, at the Jinyintan Hospital in Wuhan, Hubei province, China. Another 113 and 285 patients with COVID-19 were respectively recruited from Renmin Hospital of Wuhan University, Hubei province and Shenzhen Third People's Hospital, Guangdong province, China. The diagnosis of COVID-19 was confirmed by a positive real-time reverse transcriptase polymerase-chain-reaction test of SARS-CoV-2 on nasal and pharyngeal swab specimens from patients. Two recent surveys of ABO blood group distribution of 3,694 normal people from Wuhan City and 23,386 normal people from Shenzhen City were used as comparison controls for the Wuhan and Shenzhen patients with COVID-19, respectively. Statistical analyses were performed using one-way ANOVA and 2-tailed \( \chi^2 \). Data from different hospitals were meta-analyzed using random effects models, with calculation of odds ratio (OR) and 95% confidence interval (CI). Statistical analyses were performed using SPSS software (version 16.0) and STATA software (version 13).

**RESULTS**

The ABO blood group in 3,694 normal people in Wuhan displayed a percentage distribution of 32.16%, 24.90%, 9.10% and 33.84% for A, B, AB and O, respectively, while the 1,775 patients with COVID-19 from Wuhan Jinyintan Hospital showed an ABO distribution of 37.75%, 26.42%, 10.03% and 25.80% for A, B, AB and O, respectively. The proportion of blood group A in patients with COVID-19 was significantly higher than that in normal people, being 37.75% in the former vs 32.16% in the later \( (P < 0.001) \). The proportion of blood group O in patients with COVID-19
was significantly lower than that in normal people, being 25.80% in the former vs 33.84% in the later (P < 0.001, Table 1). These results corresponded to a significantly increased risk of blood group A for COVID-19 with an OR of 1.279 (95% CI 1.136~1.440) and decreased risk of blood group O for COVID-19 with an OR of 0.680 (95% CI 0.599~0.771, Table 1) in comparison with non-A groups and non-O groups, respectively.

A similar distribution pattern of high-risk blood group A and low-risk blood group O was observed in the dead patients. Specifically, the proportions of blood groups A, B, AB and O in the 206 dead patients were 41.26%, 24.27%, 9.22% and 25.24%, respectively. Blood group O was associated with a lower risk of death compared with non-O groups, with an OR of 0.660 (95% CI 0.479~0.911, P = 0.014, Table 1). To the contrary, blood group A was associated with a higher risk of death compared with non-A groups, with an OR of 1.482 (95% CI 1.113~1.972, P = 0.008, Table 1).

We next examined 113 patients with COVID-19 from another hospital in Wuhan City, the Renmin Hospital of Wuhan University, and found a similar risk distribution trend of ABO blood groups for the infection. Specifically, compared with non-O groups, blood group O were significantly associated with a lower risk of infection, with an OR of 0.644 (95% CI 0.418~0.993, P = 0.045, Table 1). Compared with non-A blood groups, blood group A displayed higher relative risk (OR=1.396; 95% CI 0.952~2.048) than those observed in patients from Wuhan Jinyintan Hospital, although the associations did not reach statistical significance likely due to the small
sample size.

The ABO blood group in 23368 normal people in Shenzhen displayed a percentage distribution of 28.77%, 25.14%, 7.32% and 38.77% for A, B, AB and O, respectively. Analysis of 285 patients with COVID-19 from Shenzhen showed proportions of blood groups A, B, AB and O to be 28.77%, 29.12%, 13.68% and 28.42%, respectively. Similarly, a significantly lower risk of infection was associated with blood group O (OR, 0.627; 95% CI 0.484~0.812). Additionally, we found that blood group AB had an increased risk of infection (OR, 2.008; 95% CI 1.427~2.824, Table 1). Also, the average age of the 285 patients was 45.1±18.6 years, including 147 men and 138 women. We found no significant difference in patient age among different ABO groups (F = 0.135 ; P = 0.939).

Figure 1 shows the estimates of ORs of the risk of ABO blood groups for COVID-19 on the pooled data from the three hospitals by random effects models. Again, the results showed that blood group A was associated with a significantly higher risk for COVID-19 (OR, 1.21; 95% CI 1.02~1.43, P = 0.027) compared with non-A blood groups, whereas blood group O was associated with a significantly lower risk for the infection (OR, 0.67; 95% CI 0.60~0.75, P < 0.001) compared with non-O blood groups. Compared with other ABO blood groups, AB blood group (OR, 1.48, 95% CI 0.97~2.24) and B blood group (OR, 1.09, 95% CI 0.98~1.22) seemed to have a higher risk of infection, although the associations did not reach statistical significance.

We next investigate whether the people’s age and gender as two risk factors
influence the ABO blood group distribution among patients with COVID-19. The distribution of ABO blood groups is known to have no sex and age predilections. For example, by analyzing the blood type of more than ninety thousands normal people, it was out that the percentage of A, B, AB and O blood types were essentially the same among different age groups and among different genders. Thus we used the ABO blood group distribution of 3,694 normal people in Wuhan area as control to compare with different age groups and gender groups. When all patients from Jinyintan Hospital and Renmin Hospital in Wuhan city were combined together (1,888 patients together) and grouped into three age groups (less 40, 41-59, over 60 years old ages), the ABO blood group distribution did not change among the three age groups (Table S1). Similarly, the ABO blood group distribution did not have much change when men and woman of patient with COVID-19 were considered separately (Table S1).

DISCUSSION

In this study, we found that ABO blood groups displayed different association risks for the infection with SARS-CoV-2 resulting in COVID-19. Specifically, blood group A was associated with an increased risk whereas blood group O was associated with a decreased risk, thus demonstrating that the ABO blood type is a biomarker for differential susceptibility of COVID-19. These findings are consistent with similar risk patterns of ABO blood groups for other coronavirus infection found in previous studies. For example, Cheng et al. reported that the SARS-CoV infection
susceptibility in Hong Kong was differentiated by the ABO blood group systems. The authors found that compared with non-O blood group hospital staff, blood group O hospital staff had a lower chance of getting infected. Patrice et al. found that anti-A antibodies specifically inhibited the adhesion of SARS-CoV S protein-expressing cells to ACE2-expressing cell lines. Given the nucleic acid sequence similarity and receptor angiotensin-converting enzyme 2 (ACE2) binding similarity between SARS-CoV and SARS-CoV-2, the lower susceptibility of blood group O and higher susceptibility of blood group A for COVID-19 could be linked to the presence of natural anti-blood group antibodies, particularly anti-A antibody, in the blood. This hypothesis will need direct studies to prove. There may also be other mechanisms underlying the ABO blood group-differentiated susceptibility for COVID-19 that require further studies to elucidate.

**Conclusion**

In summary, we for the first time report a link between COVID-19 susceptibility and the ABO blood group, demonstrating the latter to be a biomarker differentiating the former. Specifically, people with blood group A have a higher risk whereas people with blood group O have a lower risk for SARS-CoV-2 infection and COVID-19 severity. This study may have potential clinical implications given the current COVID-19 crisis: (1) People with blood group A might need particularly strengthened personal protection to reduce the chance of infection; (2) SARS-CoV-2-infected patients with blood group A might need to receive more vigilant surveillance and
aggressive treatment; (3) It might be helpful to introduce ABO blood typing in both patients and medical personal as a routine part of the management of SARS-CoV-2 and other coronavirus infections, to help define the management options and assess risk exposure levels of people. It should be emphasized that due to the imitations discussed above, one should be cautious to use this study to guide clinical practice at this time. This study encourages further studies.

**Author contributions statement**

P.G.W. and G.Y.Y. conceived, designed and supervised the overall study. P.G.W., M.X., G.Y.Y., L.Z., and X.Y.Z. supervised and administered the project. L.Z., H.P.H. and T.L. collected and verified ABO blood types of patients from Wuhan Jinyintan Hospital. X.Y.Z. and D.L. collected and verified ABO blood types of patients from Renmin Hospital of Wuhan University. Z.Z., L.L. and Y.Y. collected and verified ABO blood types of patients from Second Affiliated Hospital, Southern University of Science and Technology. Y.J.H., B.S., Y.R.L., X.H.W. and M.L.W. collected and verified the data. D.F.G., X.F.L., Y.K.L., Z.J., M.X., and P.G.W. analyzed the data. P.G.W., J.Z., G.Y.Y. and M.X., wrote and revised the paper. All authors read and approved the final manuscript.

**PATIENTS AND PUBLIC INVOLVEMENT**

This was a retrospective case series study and no patients were directly involved in the study design, setting the research questions, or the outcome measures directly.
patients were asked to advise on interpretation or writing up of results.

**Funding:** No funding.

**Competing interest statement**

The authors declare that they have no competing financial interests.

**Ethical approval**

This study received approval from the Research Ethics Committees of the participating institutions, which waived informed patient consent because the study only involved retrospective review of clinical data and because of the urgent nature of the study to investigate a new serious infections disease.

**Patient consent:** Waived

**Data sharing:** No additional data available.

**Data Availability Statement**

The data used to support the findings of this study are included within the article.
Reference

1. Chen N Zhou M Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; (published online Jan 29.) https://doi.org/10.1016/S0140-6736(20)30211-7.

2. Batool Z, Durrani SH, Tariq S. Association Of Abo And Rh Blood Group Types To Hepatitis B, Hepatitis C, Hiv And Syphilis Infection, A Five Year' Experience In Healthy Blood Donors In A Tertiary Care Hospital. J Ayub Med Coll Abbottabad. 2017 Jan-Mar; 29(1):90-92.

3. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, Stewart P, LePendu J, Baric R. Human susceptibility and resistance to Norwalk virus infection. J Nat Med. 2003 May; 9(5):548-53. Epub 2003 Apr 14.

4. Cheng Y, Cheng G, Chui CH, Lau FY, Chan PK, Ng MH, Sung JJ, Wong RS. ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA. 2005 Mar 23; 293(12):1450-1.

5. Xu P, Xiong Y, Cao K. Distribution of ABO and RhD blood group among Healthy Han population in Wuhan. J Clin Hematol (China). 2015(28):837.
6. Chen, C. Distribution of ABO and Rh (D) blood group and quality analysis. Int J Lab Med, 2010 Jan; 31(1):77-8.

7. Zhou Y. The distribution of ABO blood groups in blood donors and the shortage of blood donation in Jinan from 2010-2013. (Doctoral dissertation) (http://cdmd.cnki.com.cn/Article/CDMD-10422-1015372555.htm)

8. Guillon P, Clément M, Sébille V, Rivain JG, Chou CF, Ruvoën-Clouet N, Le Pendu J. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology. 2008 Dec;18(12):1085-93.

9. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Jan 30;. doi: 10.1016/S0140-6736(20)30251-8.

10. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Lurzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting
enzyme 2 is a functional receptor for the SARS coronavirus. J Nature. 2003 Nov 27;426(6965):450-4.

11. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S, The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv 929042 [Preprint]. 31 January 2020. doi:10.1101/2020.01.31.929042.

12. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J. Virol. JVI.00127-20 (2020). doi:10.1128/JVI.00127-20 pmid:31996437.
Table 1. The ABO blood group distribution in patients with COVID-19 and normal controls.

| Blood Group | Controls (Wuhan Area) | Wuhan Jinyintan Hospital | Deaths | Renmin Hospital of Wuhan University | Controls (Shenzhen area) | Patients from Shenzhen Third People's Hospital |
|-------------|-----------------------|--------------------------|--------|-----------------------------------|--------------------------|-----------------------------------------------|
|             | A 1188 (32.16%)       | 1775 (37.75%)            | 206    | 113                               | 23386 (28.77%)          | 285                                           |
|             | B 920 (24.90%)        | 670 (26.42%)             | 85     | 45 (39.82%)                       | 6728 (28.77%)           | 82 (28.77%)                                    |
|             | AB 336 (9.10%)        | 469 (178 (10.03%)       | 50     | 25 (22.12%)                       | 5880 (25.14%)           | 83 (29.12%)                                    |
|             | O 1250 (33.84%)       | 1258 (10.03%)            | 19     | 15 (13.3%)                        | 1712 (7.32%)            | 39 (13.68%)                                    |
|             |                       |                          |        |                                   |                          | 81 (28.42%)                                    |
| Controls   | 3694                  |                          |        |                                   | 23386                    | 285                                           |
| (Wuhan Area)|                       |                          |        |                                   |                          |                                               |
| Wuhan      | Jinyintan Hospital    |                          |        |                                   |                          |                                               |
| Patients   | 1775                  |                          |        |                                   | 113                      | 285                                           |
|            | χ2 16.431             |                          |        |                                   | 2.601                    | 0.000                                         |
|            | P <0.001              |                          |        |                                   | 0.107                    | 0.000                                         |
|            | OR 1.279              |                          |        |                                   | 1.396                    | 0.142                                         |
|            | 95%CI 1.136~1.440     |                          |        |                                   | 0.952~1.232              | 0.952~1.344                                    |
|            |                       |                          |        |                                   | 0.920~1.349              | 0.920~1.349                                    |
|            |                       |                          |        |                                   | 0.680                    | 0.680                                         |
|            |                       |                          |        |                                   | 0.599~0.771              | 0.599~0.771                                    |
|            |                       |                          |        |                                   |                          |                                               |
| Deaths     | 206                   |                          |        |                                   | 206                      | 113                                           |
|            | χ2 6.944              |                          |        |                                   | 2.601                    | 0.000                                         |
|            | P 0.008               |                          |        |                                   | 0.107                    | 0.000                                         |
|            | OR 1.482              |                          |        |                                   | 1.396                    | 0.142                                         |
|            | 95%CI 1.113~1.972     |                          |        |                                   | 0.952~2.048              | 0.952~1.344                                    |
|            |                       |                          |        |                                   | 0.920~1.344              | 0.920~1.344                                    |
|            |                       |                          |        |                                   | 0.680                    | 0.680                                         |
|            |                       |                          |        |                                   | 0.599~0.771              | 0.599~0.771                                    |
|            |                       |                          |        |                                   |                          |                                               |
| Renmin     | Hospital of Wuhan     |                          |        |                                   | 113                      | 285                                           |
| University | patients              |                          |        |                                   | 45 (39.82%)              | 82 (28.77%)                                    |
|            | χ2 2.601              |                          |        |                                   | 0.107                    | 0.000                                         |
|            | P 0.107               |                          |        |                                   | 1.396                    | 0.142                                         |
|            | OR 1.956              |                          |        |                                   | 0.952~2.048              | 0.952~1.344                                    |
|            | 95%CI 0.952~2.048     |                          |        |                                   | 0.920~1.344              | 0.920~1.344                                    |
|            |                       |                          |        |                                   | 0.680                    | 0.680                                         |
|            |                       |                          |        |                                   | 0.599~0.771              | 0.599~0.771                                    |
|            |                       |                          |        |                                   |                          |                                               |
| Controls   | (Shenzhen area)        |                          |        |                                   | 23386                    | 285                                           |
| (Shenzhen  | area)                 |                          |        |                                   | 6728 (28.77%)           | 82 (28.77%)                                    |
| Patients   | from Shenzhen Third   |                          |        |                                   | 5880 (25.14%)           | 83 (29.12%)                                    |
| People's   | People's Hospital      |                          |        |                                   | 1712 (7.32%)            | 39 (13.68%)                                    |
|            | χ2 0.000              |                          |        |                                   | 0.000                    | 0.000                                         |
|            | P 1.000               |                          |        |                                   | 1.000                    | 0.000                                         |
|            | OR 1.000              |                          |        |                                   | 1.000                    | 0.000                                         |
|            | 95%CI 0.773~1.294     |                          |        |                                   | 0.946~1.582             | 1.427~2.824                                    |
|            |                       |                          |        |                                   | 1.427~2.824             | 1.427~2.824                                    |
|            |                       |                          |        |                                   | 0.627                    | 0.627                                         |
|            |                       |                          |        |                                   | 0.484~0.812             | 0.484~0.812                                    |

CI, confidence interval; OR, odds ratio; *P value was calculated by 2-tailed χ2
Figure 1. Meta-analysis of the risk of ABO blood groups for COVID-19 in three hospitals. The X-axis represents the point estimate of odds ratio and corresponding 95% confidence interval; the Y-axis represents the source of study patients. OR, odds ratio. CI, confidence interval.
Table S1. Influence of age and gender on the ABO blood group distribution in patients with COVID-19 from two Wuhan hospitals.

| Blood Group | A      | B      | AB     | O      |
|-------------|--------|--------|--------|--------|
|             | 3694 Control (Wuhan area) | 1188 (32.16%) | 920 (24.90%) | 336 (9.10%) | 1250 (33.84%) |
| Wuhan       | 1888 patients | 715 (37.87%) | 494 (26.17%) | 193 (10.22%) | 486 (25.74%) |
| $\chi^2$    | 17.880 | 0.983  | 1.720  | 37.852 |
| $P$         | **<0.001** | 0.321  | 0.190  | **<0.001** |
| OR          | 1.286  | 1.069  | 1.138  | 0.678  |
| 95%CI       | 1.145~1.444 | 0.941~1.213 | 0.944~1.371 | 0.599~0.767 |

Less than 40 years

| Blood Group | A      | B      | AB     | O      |
|-------------|--------|--------|--------|--------|
|             | 100 (36.63%) | 78 (28.57%) | 21 (7.69%) | 74 (27.11%) |
| $\chi^2$    | 2.117  | 1.625  | 0.452  | 4.883  |
| $P$         | **0.146** | 0.202  | 0.501  | **0.027** |
| OR          | 1.219  | 1.206  | 0.833  | 0.727  |
| 95%CI       | 0.944~1.575 | 0.918~1.585 | 0.526~1.318 | 0.552~0.958 |

Between 41-59 years

| Blood Group | A      | B      | AB     | O      |
|-------------|--------|--------|--------|--------|
|             | 275 (39.01%) | 176 (24.96%) | 71 (10.07%) | 183 (25.96%) |
| $\chi^2$    | 12.197 | **<0.001** | 0.559  | 16.385 |
| $P$         | 1.349  | 1.003  | 1.119  | 0.685  |
| OR          | 1.142~1.593 | 0.833~1.208 | 0.855~1.466 | 0.572~0.822 |
| 95%CI       | 1.142~1.593 | 0.833~1.208 | 0.855~1.466 | 0.572~0.822 |

Over 60 years

| Blood Group | A      | B      | AB     | O      |
|-------------|--------|--------|--------|--------|
|             | 340 (37.36%) | 240 (26.37%) | 101 (11.10%) | 229 (25.16%) |
| $\chi^2$    | 8.679  | 0.759  | 3.181  | 24.797 |
| $P$         | **0.003** | 0.384  | **0.075** | **<0.001** |
| OR          | 1.258  | 1.080  | 1.248  | 0.657  |
| 95%CI       | 1.082~1.463 | 0.916~1.274 | 0.986~1.579 | 0.558~0.775 |

male 1030

| Blood Group | A      | B      | AB     | O      |
|-------------|--------|--------|--------|--------|
|             | 403 (39.13%) | 275 (26.70%) | 101 (9.81%) | 251 (24.37%) |
| $\chi^2$    | 17.187 | 1.278  | 0.403  | 32.883 |
| $P$         | **<0.001** | 0.258  | 0.526  | **<0.001** |
| OR          | 1.356  | 1.098  | 1.087  | 0.630  |
| 95%CI       | 1.175~1.564 | 0.939~1.285 | 0.860~1.373 | 0.538~0.738 |

female 858

| Blood Group | A      | B      | AB     | O      |
|-------------|--------|--------|--------|--------|
|             | 312 (36.36%) | 219 (25.52%) | 92 (10.72%) | 235 (27.39%) |
| $\chi^2$    | 5.379  | 0.111  | 1.976  | 12.884 |
| $P$         | **0.020** | 0.739  | 0.160  | **<0.001** |
| OR          | 1.205  | 1.033  | 1.200  | 0.738  |
| 95%CI       | 1.032~1.408 | 0.871~1.226 | 0.941~1.531 | 0.625~0.870 |

CI, confidence interval; OR, odds ratio; *P value was calculated by 2-tailed $\chi^2$